论文部分内容阅读
在前不久举行的第19届长城国际心脏病学大会上,记者目睹以“PCI(经皮冠状动脉介入治疗)基础与规范”为主题的会议现场座无虚席,甚至连过道及门口外都挤满听者。这种火爆场景从侧面反映,2007年7月由卫生部下发的《心血管疾病介入诊疗技术管理规范》(以下简称《规范》)似乎对各地PCI并未起到有效规范和“降温”。此《规范》为何没有达到人们预想的效果?《规范》中最具争议的是什么?通过PCI在中国的演进,是否能给其他类似的新技术(如心脏射频消融技术等)在中国的推广提供借鉴,从而达到维护患者安全、维持医疗市场有序竞争的目的?专家们如是说。
At the 19th Great Wall International Conference on Cardiology, which was held not long ago, the reporter witnessed the packed meeting room with the theme of “PCI (Percutaneous Coronary Intervention) Full listener. This hot scene from the side reflected in July 2007 issued by the Ministry of Health, ”Cardiovascular Intervention Treatment Technical Management Practices“ (hereinafter referred to as ”norms“) PCI seems to have not played around the effective norms and . Why did the Code fail to achieve what people expected? What is the most controversial issue in the ”Code"? Will the promotion of other similar new technologies (such as cardiac radiofrequency ablation) in China be promoted through PCI in China? Provide reference, so as to achieve the purpose of maintaining patient safety and maintaining orderly competition in the medical market? Experts say.